natgillin/translations-raw huggingface dataset:
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on the surface of cells in the body.
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo oblikovano tako, da prepozna in se veže na specifično strukturo (imenovano antigen), ki se nahaja na površini celic v telesu.
Raptiva is given by injection under the skin.
Zdravilo Raptiva se daje z injekcijo pod kožo.
As LFA-1 is important in helping the lymphocytes to stick to cells in the skin, efalizumab reduces the inflammation in the skin that causes psoriasis.
Ker LFA-1 pomembno pomaga limfocitom, da se vežejo na celice v koži, efalizumab zmanjšuje vnetje kože, ki povzroča psoriazo.
Raptiva has been studied in five main studies involving over 3,000 patients with moderate to severe plaque psoriasis.
Zdravilo Raptiva so preučevali v petih glavnih študijah z več kot 3000 bolniki z zmerno do hudo psoriazo s plaki.
Raptiva was more effective than placebo at improving the symptoms of psoriasis.
Zdravilo Raptiva je bilo pri izboljšanju simptomov psoriaze učinkovitejše od placeba.
Looking only at the ‘high need' patients in this study, 30% of those receiving Raptiva responded to treatment, compared with 3% of those receiving
Če upoštevamo le bolnike z „visoko potrebo“ iz te študije, se je na zdravljenje odzvalo 30 % izmed tistih, ki so prejemali zdravilo Raptiva, v primerjavi s 3 % bolnikov, ki so prejemali placebo.
It contains the active
Vsebuje zdravilno
In the fifth study, overall, 166 (31%) of the 529 patients receiving Raptiva responded to treatment, compared with 11 (4%) of the 264 receiving placebo.
V peti študiji se je na zdravljenje odzvalo skupaj 166 (31 %) izmed 529 bolnikov, ki so prejemali zdravilo Raptiva, v primerjavi z 11 (4 %) izmed 264 bolnikov, ki so prejemali placebo.
Efalizumab has been designed to bind to part of a protein called LFA-1 on the surface of lymphocytes, a type of white blood cell that is involved in the inflammation process.
Efalizumab je zasnovan tako, da se veže na del beljakovine, imenovane LFA-1, na površini limfocitov, tj. na vrsto belih krvničk, ki sodeluje pri vnetnem procesu.
Looking at the results of the first four studies taken together, 320 (26%) of the 1,213 patients receiving 1.0 mg/kg Raptiva per week responded to treatment, compared with 25 (4%) of the 715 receiving placebo.
Če pogledamo rezultate prvih štirih študij skupaj, ugotovimo, da se je na zdravljenje odzvalo 320 (26 %) izmed 1213 bolnikov, ki so prejemali 1,0 mg/kg zdravila Raptiva tedensko, v primerjavi s 25 (4 %) izmed 715 bolnikov, ki so prejemali placebo.
The most common side effects with Raptiva (seen in more than 1 patient in 10) are mild to moderate flu-like symptoms including headache, fever, chills, nausea (feeling sick), myalgia (muscle pain), and leucocytosis and lymphocytosis (increased white blood cell counts).
Najpogostejši neželeni učinki pri jemanju zdravila Raptiva (opaženi pri več kot 1 izmed 10 bolnikov) so blagi do zmerni gripi podobni simptomi, kot so glavobol, povišana telesna temperatura, mrzlica, navzeja (slabost), mialgija (bolečina v mišicah) ter levkocitoza in limfocitoza (zvišana koncentracija belih krvničk).
It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of
Prav tako ga ne smejo uporabljati bolniki, ki so imeli raka, ki imajo aktivno tuberkulozo ali druge hude okužbe, druge oblike psoriaze ali oslabljen imunski sistem.
Raptiva treatment should be initiated by a doctor who specialises in dermatology (the treatment of skin conditions).
Zdravljenje z zdravilom Raptiva mora uvesti zdravnik, specializiran za dermatologijo (zdravljenje kožnih obolenj).
The active substance in Raptiva, efalizumab, is a monoclonal antibody.
Zdravilna učinkovina zdravila Raptiva, efalizumab, je monoklonsko protitelo.
In all studies, the effectiveness of Raptiva was compared with that of placebo (a dummy treatment).
V vseh študijah so učinkovitost zdravila Raptiva primerjali z učinkovitostjo placeba (zdravila brez zdravilne učinkovine).
Raptiva should not be used in people who may be hypersensitive (allergic) to efalizumab or any of the other ingredients.
Zdravila Raptiva ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) efalizumab ali katero koli drugo sestavino zdravila.
Raptiva should be used with caution in patients who have problems with their liver or
Zdravilo Raptiva je treba pri bolnikih, ki imajo težave z jetri ali ledvicami, uporabljati previdno.
Raptiva is used for the treatment of adults with moderate to severe chronic (long-term) plaque psoriasis (a disease causing red, scaly patches on the skin).
Zdravilo Raptiva se uporablja za zdravljenje odraslih z zmerno do hudo kronično (dolgotrajno) psoriazo (luskavico) s plaki (bolezen, ki povzroča rdeče, luskaste spremembe na koži).
It is used in patients who have failed to respond to or cannot take other systemic (whole-body) treatments for psoriasis, including ciclosporin, methotrexate and PUVA (psoralen ultraviolet-A).
Uporablja se pri bolnikih, ki se ne odzivajo na ali ne morejo jemati drugih sistemskih zdravil (zdravil, ki delujejo na celotno telo) za psoriazo, vključno s ciklosporinom, metotreksatom in PUVA (psoralen v kombinaciji z obsevanjem z UVA žarki).
PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet
PUVA je vrsta zdravljenja, pri katerem prejme bolnik, preden je izpostavljen ultravijolični svetlobi, zdravilo, ki vsebuje spojino psoralen.
Raptiva is a powder and solvent that are made up into a solution for injection.
Zdravilo Raptiva je prašek in vehikel za pripravo raztopine za injiciranje.
Therefore, the Committee decided that Raptiva's benefits are greater than its risks for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contra-indication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.
Odbor je zato odločil, da so koristi zdravila Raptiva pri zdravljenju odraslih bolnikov z zmerno do hudo kronično psoriazo s plaki, ki se ne odzivajo na druga sistemska zdravljenja, vključno s ciklosporinom, metotreksatom in PUVA, oziroma imajo zanje kontraindikacije ali jih ne prenašajo, večje od z njim povezanih tveganj.
This improves
To izboljša simptome bolezni.
The full EPAR for Raptiva can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Raptiva je na voljo tukaj.
For the full list of all side effects reported with Raptiva, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila
The studies included patients who had not taken other treatments for psoriasis in the past, as well as those who had taken other treatments.
Rezultati so bili pri bolnikih, ki so predhodno prejemali sistemska zdravila za psoriazo, podobni kot pri bolnikih, ki teh zdravil niso prejemali.
Therapy should only be continued in patients who have responded to treatment.
Maksimalni posamični odmerek je 200 mg. Zdravljenje se sme nadaljevati samo pri bolnikih, ki so se odzvali na zdravljenje.
The main measure of effectiveness was the average change in the blood pressure.
Glavno merilo učinkovitosti je bila povprečna sprememba krvnega tlaka.
The European Commission granted a marketing authorisation valid throughout the European Union for Exforge HCT on 16 October 2009.
Evropska komisija je dovoljenje za promet z zdravilom Exforge HCT, veljavno po vsej Evropski uniji, odobrila dne 16. oktobra 2009.
The full EPAR for Exforge HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Exforge HCT je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
amlodipine / valsartan / hydrochlorothiazide
amlodipin/valsartan/hidroklorotiazid
Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets.
Ker se kombinacija treh zdravilnih učinkovin uporablja že vrsto let, je družba predstavila študije, ki kažejo, da se tableta, ki vsebuje vse tri učinkovine, v telesu absorbira enako kot tablete z ločenimi učinkovinami.
This is a summary of the European public assessment report (EPAR) for Exforge HCT.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Exforge HCT.
It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg.
Na voljo je v obliki tablet, ki vsebujejo amlodipin, valsartan in hidroklorotiazid v naslednjih količinah: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg in 10/320/25 mg.
For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Exforge HCT preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II.
Valsartan je antagonist receptorja za angiotenzin II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning.
Zdravilo Exforge HCT se jemlje peroralno, in sicer se zaužije ena tableta enkrat na dan ob isti uri, če je le mogoče, zjutraj.
The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Exforge HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone.
Kombinacija treh zdravilnih učinkovin ima aditiven učinek, saj zniža krvni tlak bolj kot vsako posamezno zdravilo posebej.
The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure.
Glavna študija je pokazala koristnost uporabe največjega odmerka zdravila Exforge HCT pri zniževanju krvnega tlaka.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Exforge HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Amlodipine is a ‘calcium channel blocker'.
Amlodipin je zaviralec kalcijevih kanalčkov.
The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU).
Tri zdravilne učinkovine v zdravilu Exforge HCT so zdravila proti zvišanemu krvnemu tlaku, ki se že uporabljajo v Evropski uniji (EU).
Exforge HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide.
Zdravilo Exforge HCT se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih je krvni tlak že ustrezno uravnan z uporabo kombinacije amlodipina, valsartana in hidroklorotiazida.
The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention).
Najpogostejši neželeni učinki zdravila Exforge HCT (opaženi pri 1 do 10 bolnikih od 100) so hipokaliemija (nizka raven kalija v krvi), omotica, glavobol, hipotenzija (nizek krvni tlak), dispepsija (zgaga), polakisurija (neobičajno pogosto uriniranje), utrujenost in edem (zadrževanje tekočine).
Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide.
Exforge HCT je zdravilo, ki vsebuje tri zdravilne učinkovine amlodipin, valsartan in hidroklorotiazid.
The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Exforge HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.
Povprečno znižanje krvnega tlaka je bilo okrog 39,7/24,7 mmHg pri bolnikih, ki so prejemali zdravilo Exforge HCT, v primerjavi z 32/19,7 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/hidroklorotiazid, 33,5/21,5 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/amlodipin, in 31,5/19,5 mmHg pri bolnikih, ki so prejemali kombinacije hidroklorotiazid/amlodipin.
For all doses, Exforge HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken seperately.
Pri vseh odmerkih je zdravilo Exforge HCT izpolnilo tudi zahteve, s katerimi je bilo dokazano, da je primerljivo s kombinacijami posameznih zdravilnih učinkovin, vzetih ločeno.
The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.
Dnevni odmerek učinkovin zdravila Exforge HCT ne sme biti večji od 10 mg amlodipina, 320 mg valsartana in 25 mg hidroklorotiazida.
What benefit has Exforge HCT shown during the studies?
Kakšne koristi je zdravilo Exforge HCT izkazalo med študijami?
Treatment with the highest strength of Exforge HCT was more effective at treating hypertension than dual combinations containing any of the two active substances.
Zdravljenje z največjim odmerkom zdravila Exforge HCT je bilo pri zdravljenju hipertenzije učinkovitejše od zdravljenja z dvojnimi kombinacijami, ki so vsebovale po dve zdravilni učinkovini.
For the full list of all side effects reported with Exforge HCT, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Exforge HCT, glejte navodilo za uporabo.
The dose of Exforge HCT to be used is the same as the doses of three individual active substances that the patient was taking before.
Odmerek učinkovin zdravila Exforge HCT mora biti enak odmerkom treh posameznih zdravilnih učinkovin, ki jih je bolnik prejemal pred tem.
By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce.
Ker valsartan ustavi njegovo delovanje z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, hormonu prepreči učinkovanje, zaradi česar se krvne žile lahko razširijo, krvni tlak pa zniža.
It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure.
Deluje tako, da poveča izločanje seča, zaradi česar se zmanjša količina tekočine v telesu in zniža krvni tlak.
Exforge HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Exforge HCT.
Zdravila Exforge HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilne učinkovine, druge sulfonamide, derivate dihidropiridina ali katero koli drugo sestavino zdravila
By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood vessel walls to relax and widen, thereby reducing blood pressure.
Amlodipin z zmanjšanjem pretoka kalcija v celice prepreči njihovo krčenje in pomaga pri sproščanju in širjenju sten žil ter tako znižuje krvni tlak.
Other information about Exforge HCT
Druge informacije o zdravilu Exforge HCT
Exforge HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Prav tako se ne sme uporabljati v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), pri bolnikih s sladkorno boleznijo tipa 2 ali zmerno do hudo ledvično okvaro.
Finally, Exforge HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.
Zdravila Exforge HCT poleg tega ne smejo uporabljati bolniki s hipokaliemijo (nizko ravnjo kalija v krvi), hiponatriemijo (nizko ravnjo natrija v krvi) in hiperkalciemijo (visoko ravnjo kalcija v krvi), ki se ne odzivajo na zdravljenje, ter bolniki s simptomatsko hiperurikemijo (visoko koncentracijo sečne kisline v krvi).
What is the risk associated with Exforge HCT?
Kakšna tveganja so povezana z zdravilom Exforge HCT?
It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique).
Zdravila prav tako ne smejo uporabljati osebe, ki imajo obolenja jeter ali žolčnika (kot je npr. zlatenica), hude ledvične okvare, anurijo (nezmožnost izločanja urina) ali bolniki na dializi (tehniki čiščenja krvi).
In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Exforge HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide).
Poleg tega je bila izvedena glavna študija, v kateri so proučevali 2 271 bolnikov z zmerno do hudo hipertenzijo, ki so prejemali največji odmerek zdravila Exforge HCT (320 mg valsartana, 10 mg amlodipina in 25 mg hidroklorotiazida) Bolniki so osem tednov prejemali bodisi zdravilo Exforge HCT bodisi eno od treh kombinacij, ki so vsebovale le dve zdravilni učinkovini.
Why has Exforge HCT been approved?
Zakaj je bilo zdravilo Exforge HCT odobreno?
The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Exforge HCT which combines the three substances in a single tablet.
CHMP je menil, da bi uporaba zdravila Exforge HCT, pri katerem so tri zdravilne učinkovine prisotne v eni tableti, bolnikom, ki tri zdravilne učinkovine že prejemajo ločeno, omogočila doslednejše jemanje zdravila.
How has Exforge HCT been studied?
Kako je bilo zdravilo Exforge HCT raziskano?
How is Exforge HCT used?
Kako se zdravilo Exforge HCT uporablja?
What is Exforge HCT?
Kaj je zdravilo Exforge HCT?
What is Exforge HCT used for?
Za kaj se zdravilo Exforge HCT uporablja?
It is a hybrid medicine.
Je „hibridno zdravilo“.
The tablets are taken in 2 to 4 divided doses.
Tablete se jemljejo razdeljene v od 2 do 4 odmerke.
In adults, the total recommended daily dose is from 3 to 6.5 tablets, and in children from 1.5 to 4 tablets.
Pri odraslih je skupni priporočeni dnevni odmerek od 3 do 6,5 tablet, pri otrocih pa od 1,5 do 4 tablete.
What measures are being taken to ensure the safe and effective use of Cuprior?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cuprior?
Cuprior is available as 150 mg tablets.
Zdravilo Cuprior je na voljo v obliki tablet po 150 mg.
This means that it is similar to a ‘reference medicine' (in this case Trientine Dihydrochloride 300 mg capsules) also containing trientine.
To pomeni, da je podobno „referenčnemu zdravilu“ (v tem primeru zdravilu trientinijev dihidroklorid v obliki 300-miligramskih kapsul), ki tudi vsebuje trientin.
The company provided data from the published literature, which show that trientine significantly increases copper elimination in the urine.
Družba je predložila podatke iz objavljene literature, ki kažejo, da trientin bistveno poveča izločanje bakra v urinu.
Other information about Cuprior
Druge informacije o zdravilu Cuprior
The CHMP noted that trientine has been used for over 30 years to treat patients with Wilson's disease.
Odbor CHMP je upošteval, da se trientin pri zdravljenju bolnikov z Wilsonovo boleznijo uporablja več kot 30 let.
What are the benefits and risks of Cuprior?
Kakšne so koristi in tveganja, povezani z zdravilom Cuprior?
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cuprior's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cuprior večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
This is a summary of the European public assessment report (EPAR) for Cuprior.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cuprior.
The difference between Cuprior and the reference medicine is that Cuprior contains another form of trientine (trientine tetrahydrochloride) and does not need to be stored in a refrigerator.
Razlika med zdravilom Cuprior in referenčnim zdravilom je, da Cuprior vsebuje drugo vrsto trientina (trientinijev tetrahidroklorid) in ga ni treba shranjevati v hladilniku.
Cuprior should be taken on an empty stomach, at least one hour before or two hours after meals.
Zdravilo Cuprior je treba vzeti na tešče vsaj eno uro pred obrokom ali dve uri po njem.
The full EPAR for Cuprior can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cuprior je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Since Cuprior is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Cuprior hibridno zdravilo, se njegove koristi in tveganja štejejo za enake kot pri referenčnem zdravilu.
It is not intended to provide practical advice on how to use Cuprior.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Doses are adjusted according to patient response and levels of copper in the body.
Odmerki se prilagajajo glede na bolnikov odziv in ravni bakra v telesu.
It works by attaching to copper in the body and forming a complex that is then eliminated in the urine.
Deluje tako, da se veže na baker v telesu in tvori kompleks, ki se nato izloči z urinom.
Cuprior is used in patients who cannot take D-penicillamine, another medicine for this condition.
Zdravilo Cuprior se uporablja pri bolnikih, ki ne smejo jemati D-penicilamina, drugega zdravila za to bolezen.
Cuprior is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage.
Zdravilo Cuprior se uporablja za zdravljenje bolnikov, starih 5 let in več, ki imajo Wilsonovo bolezen, genetsko motnjo, pri kateri se baker iz hrane nalaga v telesu, še posebej v jetrih in možganih, kjer povzroča okvare.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cuprior have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cuprior upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.